Ceftobiprole in Critically Ill Patients: Proposal for New Dosage Regimens

Area of Science:

• Pharmacology
• Critical Care Medicine

Background:

• Ceftobiprole is a broad-spectrum cephalosporin used for pneumonia.
• Current dosing may not achieve optimal pharmacokinetic/pharmacodynamic (PK/PD) targets in critically ill patients.

Purpose of the Study:

• To evaluate if manufacturer-recommended ceftobiprole dosages achieve the PK/PD target in over 90% of critically ill patients.
• To propose adjusted dosing regimens for improved ceftobiprole efficacy in intensive care unit (ICU) settings.

Main Methods:

• Measured ceftobiprole concentrations in 27 ICU patients.
• Evaluated population pharmacokinetic models and selected the best fit (Muller's model).
• Used simulations to assess manufacturer's regimens and propose adjustments for achieving the PK/PD target (100% fT > 4 * MIC).

Main Results:

• Manufacturer dosing regimens failed to achieve the optimal PK/PD criterion in critically ill patients.
• Muller's pharmacokinetic model accurately described observed ceftobiprole concentrations.
• Adjusted dosing regimens were proposed to ensure effectiveness in at least 90% of patients.

Conclusions:

• Proposed ceftobiprole dosing regimens can guide therapy in critically ill patients.
• Individualized dosing adjustments are necessary for optimal ceftobiprole exposure.
• Monitoring ceftobiprole plasma concentrations is essential to confirm adequate patient exposure.